Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis
This is a systematic review and meta-analysis evaluating the prognostic significance of epigenetic mutations on the overall survival (OS) in Acute Myeloid Leukemia (AML). We searched for studies evaluating epigenetic mutations in AML (up to November 2018) in PubMed, Trip database and Cochrane librar...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.967657/full |
| _version_ | 1811187018951032832 |
|---|---|
| author | Fatma Al-Bulushi Fatma Al-Bulushi Rahma Al-Riyami Zainab Al-Housni Bushra Al-Abri Murtadha Al-Khabori Murtadha Al-Khabori |
| author_facet | Fatma Al-Bulushi Fatma Al-Bulushi Rahma Al-Riyami Zainab Al-Housni Bushra Al-Abri Murtadha Al-Khabori Murtadha Al-Khabori |
| author_sort | Fatma Al-Bulushi |
| collection | DOAJ |
| description | This is a systematic review and meta-analysis evaluating the prognostic significance of epigenetic mutations on the overall survival (OS) in Acute Myeloid Leukemia (AML). We searched for studies evaluating epigenetic mutations in AML (up to November 2018) in PubMed, Trip database and Cochrane library. Hazard ratio (HR) of outcomes were extracted, and random-effects model was used to pool the results. A total of 10,002 citations were retrieved from the search strategy; 42 articles were identified for the meta-analysis (ASXL1 = 7, TET2 = 8, DNMT3A = 12, IDH =15), with fair to good-quality studies. The pooled HR was 1.88 (95% CI: 1.49−2.36) for ASXL1 mutation, 1.39 (95% CI: 1.18−1.63) for TET2 mutation, 1.35 (95% CI 1.16-1.56) for DNMT3a and 1.54 (95% CI: 1.15-2.06) for IDH mutation. However, there was a substantial heterogeneity in the DNMT3a and IDH studies. In conclusion epigenetic mutations in ASXL1, TET2, DNMT3a and IDH adversely impact OS in patients with AML albeit with considerable heterogeneity and possibly publication bias. Further studies are required to address these limitations. |
| first_indexed | 2024-04-11T13:55:10Z |
| format | Article |
| id | doaj.art-97a223b8ca5a41dd96fd8b061aa4c889 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T13:55:10Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-97a223b8ca5a41dd96fd8b061aa4c8892022-12-22T04:20:22ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-11-011210.3389/fonc.2022.967657967657Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysisFatma Al-Bulushi0Fatma Al-Bulushi1Rahma Al-Riyami2Zainab Al-Housni3Bushra Al-Abri4Murtadha Al-Khabori5Murtadha Al-Khabori6Hematopathology, Oman Medical Specialty Board, Muscat, OmanHematology Department, Sultan Qaboos University Hospital, Muscat, OmanInternal Medicine, Oman Medical Specialty Board, Muscat, OmanHematology Department, Sultan Qaboos University Hospital, Muscat, OmanHematopathology, Oman Medical Specialty Board, Muscat, OmanHematology Department, Sultan Qaboos University Hospital, Muscat, OmanCollege of Medicine and Health Sciences, Sultan Qaboos University, Muscat, OmanThis is a systematic review and meta-analysis evaluating the prognostic significance of epigenetic mutations on the overall survival (OS) in Acute Myeloid Leukemia (AML). We searched for studies evaluating epigenetic mutations in AML (up to November 2018) in PubMed, Trip database and Cochrane library. Hazard ratio (HR) of outcomes were extracted, and random-effects model was used to pool the results. A total of 10,002 citations were retrieved from the search strategy; 42 articles were identified for the meta-analysis (ASXL1 = 7, TET2 = 8, DNMT3A = 12, IDH =15), with fair to good-quality studies. The pooled HR was 1.88 (95% CI: 1.49−2.36) for ASXL1 mutation, 1.39 (95% CI: 1.18−1.63) for TET2 mutation, 1.35 (95% CI 1.16-1.56) for DNMT3a and 1.54 (95% CI: 1.15-2.06) for IDH mutation. However, there was a substantial heterogeneity in the DNMT3a and IDH studies. In conclusion epigenetic mutations in ASXL1, TET2, DNMT3a and IDH adversely impact OS in patients with AML albeit with considerable heterogeneity and possibly publication bias. Further studies are required to address these limitations.https://www.frontiersin.org/articles/10.3389/fonc.2022.967657/fullAMLepigeneticsmutationASXL1Dnmt3aIDH |
| spellingShingle | Fatma Al-Bulushi Fatma Al-Bulushi Rahma Al-Riyami Zainab Al-Housni Bushra Al-Abri Murtadha Al-Khabori Murtadha Al-Khabori Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis Frontiers in Oncology AML epigenetics mutation ASXL1 Dnmt3a IDH |
| title | Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis |
| title_full | Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis |
| title_fullStr | Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis |
| title_full_unstemmed | Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis |
| title_short | Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis |
| title_sort | impact of mutations in epigenetic modifiers in acute myeloid leukemia a systematic review and meta analysis |
| topic | AML epigenetics mutation ASXL1 Dnmt3a IDH |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.967657/full |
| work_keys_str_mv | AT fatmaalbulushi impactofmutationsinepigeneticmodifiersinacutemyeloidleukemiaasystematicreviewandmetaanalysis AT fatmaalbulushi impactofmutationsinepigeneticmodifiersinacutemyeloidleukemiaasystematicreviewandmetaanalysis AT rahmaalriyami impactofmutationsinepigeneticmodifiersinacutemyeloidleukemiaasystematicreviewandmetaanalysis AT zainabalhousni impactofmutationsinepigeneticmodifiersinacutemyeloidleukemiaasystematicreviewandmetaanalysis AT bushraalabri impactofmutationsinepigeneticmodifiersinacutemyeloidleukemiaasystematicreviewandmetaanalysis AT murtadhaalkhabori impactofmutationsinepigeneticmodifiersinacutemyeloidleukemiaasystematicreviewandmetaanalysis AT murtadhaalkhabori impactofmutationsinepigeneticmodifiersinacutemyeloidleukemiaasystematicreviewandmetaanalysis |